Purchase this article with an account.
Sunil K Srivastava, Kimberly Baynes, Sumit Sharma, Arthi Venkat, Careen Lowder; The Prospective Imaging Quantification of Ocular Inflammation (IQI) Study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):175.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To prospectively utilize automated imaging measures of inflammation to follow patients with uveitis and correlate changes with visual function measures.
This is IRB approved prospective clinical trial. Patients with active uveitis were enrolled and imaged using fluorescein angiography and OCT. Visual function measures including VFQ-37, ERG and visual acuity were obtained. Algorithms for quantiifcation of retinal vascular leakage on wide field angiography, OCT segmentation, anterior chamber cell quantification by OCT and vitreous haze quantification by OCT were used. Patients were treated with standard of care therapy and followed.
To date 28 patients (19 women) have been enrolled. Baseline characteristics include an average age of 48 years old. 13 patients had a diagnosis of idiopathic panuveitis, 5 with posterior uveitis, 4 with Birdshot choroidopathy, 3 with sarcoidosis and 3 with intermediate uveitis. Baseline widefield retinal leakage measured 10% with a range from 0% to 89%. Baseline anterior chamber cell measurement by OCT was 12.5 cells/mm3 (range 0.4 to 166.8 cells/mm3). Baseline OCT Vitreous haze ratio was .208 (range .16-.26). Baseline OCT central subfield thickness was 287.85 um (range 134-669 um). Mean VFQ37 score at baseline was 77.
In this prospective study of automated imaging quantification of inflammation, mutliple measures of inflammation were obtained. On average, retinal vascular leakage as measured by wide field fluorescein angiography was prominent in most eyes. Baseline visual function measures were on average high. Changes of these scores with treatment and their relationship to visual function will be further investigated and reported.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only